MINERALCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS

MOELLER CARSTEN, KAUFMANN-REICHE ULRIKE, SCHMIDT ANJA, FUHRMANN ULRIKE, FISCHER OLIVIER-MARTIN
2008
OA: closed Metadata only
⚙ AI-generated summary by qwen3.7-flash, 2026-10-05 ⓘ

This invention describes using mineralocorticoid receptor antagonists to treat endometriosis, offering a therapeutic agent with improved effectiveness and side effect profiles that avoids bone mass loss.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endometriosis, which has a more favorable effectiveness profile and /or profile of side effects than previously available treatment therapies. W ith a mineralcorticoid receptor antagonist, endometriosis can be lastingly t reated without resulting in a loss of bone mass.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-23T09:30:01.253652+00:00